Hanzhong Li
Overview
Explore the profile of Hanzhong Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang H, Jiang S, Luo H, Zhou F, He D, Ma L, et al.
Signal Transduct Target Ther
. 2024 Dec;
9(1):351.
PMID: 39690158
The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) significantly enhanced radiographic progression-free and overall survival...
2.
Zhou Y, Ji Z, Yan W, Zhou Z, Li H, Xiao Y
Oncol Rep
. 2024 Sep;
52(5).
PMID: 39301643
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that certain of the Transwell invasion assay data shown in Fig. 3B on...
3.
Zhao Y, Zhang Z, Wang S, Wen J, Wang D, Ji Z, et al.
Front Surg
. 2024 Apr;
11:1348737.
PMID: 38645508
Objective: To review and summarize the characteristics and therapy of paraganglioma of the urinary bladder (PUB). Method: Patients who underwent the operation in Peking Union Medical College Hospital between January...
4.
Cai Y, Li H, Zhang Y
Oncol Rep
. 2024 Mar;
51(4).
PMID: 38426576
Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that there appeared to be several instances of overlapping data panels comparing...
5.
Wang W, Deng J, Li H, Ji Z, Wen J
Front Endocrinol (Lausanne)
. 2023 Aug;
14:1171045.
PMID: 37529597
Background: Due to the location of paragangliomas (PGLs) behind the retrohepatic segment of inferior vena cava (IVC), it is difficult to expose and resect the tumor. Case Presentation: A tumor...
6.
Liang Z, Yuliang C, Zhu M, Zhou Y, Wu X, Li H, et al.
Eur J Med Res
. 2023 Jun;
28(1):181.
PMID: 37268989
Background: This study aims to compare the clinical outcomes after performing radical prostatectomy (RP) or low-dose-rate brachytherapy (LDR) for patients with intermediate-risk prostate cancer (IRPC). Methods: We performed a retrospective...
7.
Transmission electron microscopy assessment of a novel method for isolating pure exosomes from serum
Wen J, Zhang Z, Feng G, Zhang Y, Li H, Lambert C, et al.
Biotech Histochem
. 2023 May;
98(6):391-395.
PMID: 37125533
Serum exosomes frequently are used for liquid biopsy. Serum exosomes normally are isolated using ultracentrifugation; however, ultracentrifugation is time-consuming, labor intensive and requires a high-speed centrifuge. Many commercial kits use...
8.
Gu W, Han W, Luo H, Zhou F, He D, Ma L, et al.
Lancet Oncol
. 2022 Sep;
23(10):1249-1260.
PMID: 36075260
Background: Rezvilutamide, a novel androgen-receptor inhibitor with low blood-brain barrier penetration, has shown potent antitumour activity against metastatic castration-resistant prostate cancer. In this study, we aimed to evaluate the efficacy...
9.
Wang W, Guo G, Shi G, Wei X, Hu Z, Li H, et al.
Front Oncol
. 2022 Jul;
12:871723.
PMID: 35860575
Background: Everolimus has been approved in China for adult patients with TSC-AML (tuberous sclerosis associated renal angiomyolipomas) not requiring immediate surgery and has been previously shown to be an effective...
10.
Wang W, Zhao Y, Wang X, Wang Z, Cai Y, Li H, et al.
Genet Mol Biol
. 2022 May;
45(2):e20200387.
PMID: 35638823
We sought to explore the relationship between renal lesion features and genetic mutations in tuberous sclerosis complex (TSC) patients. TSC patients with renal lesions were subjected to TSC1/2 gene next-generation...